Corrections_Today_Summer_2024_Vol.86_No.2

knowledge gaps and proposed research priorities-overview and commentary. Addict Sci Clin Pract . Dec 8 2022;17(1):69. doi:10.1186/s13722 022-00351-0 17 World Health Organization. Guidelines for the psychosocially assisted phar macological treatment of opioid dependence . WHO Press; 2009:110. 18 Kennedy-Hendricks A, Bandara S, Merritt S, Barry CL, Saloner B. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision. Drug Alcohol Depend . Sep 1 2021;226:108881. doi:10.1016/j.drugalcdep.2021.108881 19 Reichert J, Gleicher L. Probation clients’ barriers to access and use of opioid use disorder medications. Health Justice . May 28 2019;7(1):10. doi:10.1186/s40352-019-0089-6 20 Bharel M. The True Prevalence of Opioid Use Disorder Nationally Is Likely Underestimated. Am J Public Health . Feb 2019;109(2):214-215. doi:10.2105/AJPH.2018.304865 21 International Covenant on Economic Social and Cultural Rights. General Assembly resolution 2200A (XXI). 1966. Available: https://www.ohchr.org/ en/instruments-mechanisms/instruments/international-covenant-econom ic-social-and-cultural-rights. Accessed: 08 March, 2023. 22 Bruce RD, Schleifer RA. Ethical and human rights imperatives to ensure medication-assisted treatment for opioid dependence in prisons and pre-trial detention. Int J Drug Policy . Feb 2008;19(1):17-23. doi:10.1016/j. drugpo.2007.11.019 23 Smith-Rohrberg D, Bruce RD, Altice FL. Research Note — Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations. Journal of Drug Issues . 2004;34(2):451-480. doi:10.1177/002204260403400210 24 Beauchamp TL, Childress JF. Principles of Biomedical Ethics . Oxford University Press; 2001. 25 Ranapurwala SI, Shanahan ME, Alexandridis AA, et al. Opioid Overdose Mortality Among Former North Carolina Inmates: 2000-2015. Am J Public Health . Sep 2018;108(9):1207-1213. doi:10.2105/AJPH.2018.304514 26 Ranapurwala SI, Figgatt MC, M. R, et al. Opioid Overdose Deaths Among Formerly Incarcerated Persons and the General Population: North Carolina, 2000‒2018. American Journal of Public Health . 2022;112(2):300-303. doi:10.2105/ajph.2021.306621 27 Merrall EL, Kariminia A, Binswanger IA, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction . Sep 2010;105(9):1545-54. doi:10.1111/j.1360-0443.2010.02990.x 28 Waddell EN, Baker R, Hartung DM, et al. Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. Health Justice . Jul 10 2020;8(1):18. doi:10.1186/s40352-020-00113-7 29 Dowden C, Brown SL. The role of substance abuse factors in predicting recidivism: A Meta-analysis. Psychology, Crime & Law . 2002/09/01 2002;8(3):243-264. doi:10.1080/10683160208401818 30 Belenko S, Foltz C, Lang MA, Sung H-E. Recidivism Among High-Risk Drug Felons. Journal of Offender Rehabilitation . 2004/12/31 2004;40(1 2):105-132. doi:10.1300/J076v40n01_06 31 Mitchell O, Wilson DB, MacKenzie DL. Does incarceration-based drug treatment reduce recidivism? A meta-analytic synthesis of the research.

Journal of Experimental Criminology . 2007/12/01 2007;3(4):353-375. doi:10.1007/s11292-007-9040-2 32 Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend . Jan 1 2009;99(1-3):222-30. doi:10.1016/j. drugalcdep.2008.08.006 33 Fu JJ, Zaller ND, Yokell MA, Bazazi AR, Rich JD. Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States. J Subst Abuse Treat . May-Jun 2013;44(5):502-5. doi:10.1016/j.jsat.2012.10.005 34 Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug and Alcohol Dependence . 2014/09/01/ 2014;142:33-40. doi:10.1016/j. drugalcdep.2014.05.011 35 Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend . Sep 1 2014;142:33-40. doi:10.1016/j.drugalcdep.2014.05.011 36 Thakrar AP, Alexander GC, Saloner B. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. JAMA Netw Open . Dec 1 2021;4(12):e2138807. doi:10.1001/jamanetworkopen.2021.38807 37 Scott CK, Grella CE, Dennis ML, Carnevale J, LaVallee R. Availability of best practices for opioid use disorder in jails and related training and resource needs: findings from a national interview study of jails in heavily impacted counties in the U.S. Health Justice . Dec 20 2022;10(1):36. doi:10.1186/s40352-022-00197-3 38 Brezel ER, Powell T, Fox AD. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. Subst Abus . 2020;41(2):150-154. doi:10.1080/08897077.2019.1695706 39 Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther . Nov 2002;303(2):695-703. doi:10.1124/ jpet.102.038141 40 National Institute on Drug Abuse. Treating Opioid Addiction in Criminal Justice Settings. https://nida.nih.gov/publications/treating-opioid-addiction in-criminal-justice-settings. Accessed: 08 March 2023. 41 Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. Drug Alcohol Depend . Dec 1 2018;193:117-123. doi:10.1016/j. drugalcdep.2018.09.007 42 Berk J, Del Pozo B, Rich JD, Lee JD. Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting. J Addict Med . Jul-Aug 01 2022;16(4):396-398. doi:10.1097/ADM.0000000000000942 43 Evans EA, Pivovarova E, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. J Subst Abuse Treat . Jul 2022;138:108746. doi:10.1016/j.jsat.2022.108746 44 Monico LB, Gryczynski J, Lee JD, et al. Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration. J Subst Abuse Treat . Apr 2021;123:108267. doi:10.1016/j.jsat.2020.108267 →

Summer 2024 | Corrections Today

31